A recent review of 48 clinical trials involving 11,482 patients treated with PD-1 inhibitors reported a pooled relative risk for AKI of 4.19 (95% confidence interval, 1.57–11.18) when compared with non-nephrotoxic controls and an estimated incidence of 2.2% [78]. The gene discussed is PDCD1; the disease is acute kidney injury.